Holly Peay's Blog – February 2013 Archive (2)

LAST CALL: Phase 1 Survey - Risk/Benefit in Duchenne Therapies

By now you’ve probably heard about PPMD’s Risk/Benefit in Duchenne Therapies program, which aims to inform the FDA and other government agencies, biopharmaceutical companies, and others about the treatment priorities and risk tolerance of the Duchenne community. We’ve had a great response to our first survey, with more than 90 participants so…

Continue

Added by Holly Peay on February 19, 2013 at 1:56pm — 1 Comment

Risk Tolerance, Benefit Preferences, and Treatment Priorities

The Duchenne community has entered a new era where more clinical trials are coming online and the possibility of treatment is becoming a reality. Upon completion of a trial, the FDA weighs the evidence presented. But at the end of the day, it is often a value judgment about potential benefits and risks to the patient.

PPMD has launched a program – Benefit/Risk in Duchenne Therapies – to help inform the FDA and other government agencies, biopharmaceutical…

Continue

Added by Holly Peay on February 13, 2013 at 3:30pm — 2 Comments

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service